Cleveland BioLabs and Incuron Announce Growth of Curaxin CBL0137 Patent Portfolio With U.S. Composition of Matter Patent

BUFFALO, NY--(Marketwired - Mar 2, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Incuron LLC, a joint venture between the CBLI and Bioprocess Capital Ventures, announce the issuance of a composition of matter patent for Curaxin CBL0137 in the U.S.

In 2014, Incuron secured a composition of matter patent in the U.S., Patent Number 8,765,738, that covers composition of matter of CBL0137 and related curaxin compounds and provides the company protection to at least 2030. This is Incuron's second issued U.S. patent concerning CBL0137. Additional pending U.S. and international patent applications include claims to methods of use in oncology as well as various diagnostic methods. Further, Incuron has secured similar composition of matter patents covering CBL0137 in a number of important foreign markets, including Europe, China, and Russia. Incuron has also received notice that its composition of matter patent application will be granted in Japan soon.

Andrey Leonov, Ph.D., Chief Executive Officer of Incuron, commented, "Strengthening CBL0137's patent portfolio is a key facet of our partnering strategy. CBL0137 offers a novel mechanism of action and we believe that it has the potential to be used as a targeted therapeutic in a broad spectrum of cancers. Consistent with this broad potential applicability of CBL0137, these new composition of matter patents are not limited to any specific disease and therefore, along with our exciting recent clinical data, put Incuron in an excellent position to advance this unique drug."

About Cleveland BioLabs
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company's most advanced product candidate is entolimod, which is being developed for a biodefense indication and as a potential cancer treatment. The company conducts business in the United States and in the Russian Federation through two operating subsidiaries, BioLab 612, LLC and Panacela Labs, Inc. and an equity investee, Incuron, LLC. The company maintains strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, and the Children's Cancer Institute Australia. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com.

About Incuron, LLC
Incuron, LLC is a Russian Federation based joint venture founded in 2010 between Russian Closed Mutual Venture Fund "Bioprocess Capital Ventures," and Cleveland BioLabs. Incuron is developing Curaxin CBL0137 and CBL0102 for oncology and orphan indications. To learn more about Incuron, LLC, please visit the company's website at http://www.incuron.com/.

This press release contains certain forward-looking information about Cleveland BioLabs that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "will," "may," "potential," "strengthening," "potential," "put" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the receipt of patent protection to at least 2030; our ability to successfully develop and commercialize our therapeutic products; the conduct and results of our various clinical trials; our ability to obtain approval from the U.S. Food and Drug Administration or other regulatory bodies outside of the United States of our product candidates; and future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.

These risks and uncertainties include, among others, the strength and enforceability of our intellectual property rights; the Company's failure to successfully and timely develop existing and new products; the Company's collaborative relationships and the financial risks related thereto; the risks inherent in the early stages of drug development and in conducting clinical trials; the Company's ability to comply with its obligations under license agreements; the Company's inability to obtain regulatory approval in a timely manner or at all; the Company's history of operating losses and the potential for future losses, which may lead the Company to not be able to continue as a going concern. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the "Risk Factors" and "Forward-Looking Statements" described in the Company's periodic filings with the Securities and Exchange Commission.